Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries

被引:32
作者
Cinelli, Maris A. [1 ]
机构
[1] Michigan State Univ, Dept Pharmacol & Toxicol, 1355 Bogue St, E Lansing, MI 48823 USA
基金
芬兰科学院; 美国国家卫生研究院;
关键词
alkaloids; camptothecin; cancer; drug discovery; indenoisoquinolines; natural products; semisynthetic derivatives; Topoisomerase; PLANT ANTITUMOR AGENTS; PHASE-II TRIAL; CELL LUNG-CANCER; MARINE PYRROLOQUINOLINE ALKALOIDS; TERNARY CLEAVABLE COMPLEX; HUMAN TUMOR XENOGRAFT; DOUBLE-STRAND BREAKS; LACTAM SIDE-CHAIN; DNA-TOPOISOMERASE; BIOLOGICAL EVALUATION;
D O I
10.1002/med.21546
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Topoisomerases are DNA processing enzymes that relieve supercoiling (torsional strain) in DNA, are necessary for normal cellular division, and act by nicking (and then religating) DNA strands. Type 1B topoisomerase (Top1) is overexpressed in certain tumors, and the enzyme has been extensively investigated as a target for cancer chemotherapy. Various chemical agents can act as "poisons" of the enzyme's religation step, leading to Top1-DNA lesions, DNA breakage, and eventual cellular death. In this review, agents that poison Top1 (and have thus been investigated for their anticancer properties) are surveyed, including natural products (such as camptothecins and indolocarbazoles), semisynthetic camptothecin and luotonin derivatives, and synthetic compounds (such as benzonaphthyridines, aromathecins, and indenoisoquinolines), as well as targeted therapies and conjugates. Top1 has also been investigated as a therapeutic target in certain viral and parasitic infections, as well as autoimmune, inflammatory, and neurological disorders, and a summary of literature describing alternative indications is also provided. This review should provide both a reference for the medicinal chemist and potentially offer clues to aid in the development of new Top1 poisons.
引用
收藏
页码:1294 / 1337
页数:44
相关论文
共 411 条
[81]   Phase II trial of karenitecin in patients with malignant melanoma: Clinical and translational study [J].
Daud, A ;
Valkov, N ;
Centeno, B ;
Derderian, J ;
Sullivan, P ;
Munster, P ;
Urbas, P ;
DeConti, RC ;
Berghorn, E ;
Liu, ZM ;
Hausheer, F ;
Sullivan, D .
CLINICAL CANCER RESEARCH, 2005, 11 (08) :3009-3016
[82]   The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA [J].
Davies, DR ;
Mushtaq, A ;
Interthal, H ;
Champoux, JJ ;
Hol, WGJ .
JOURNAL OF MOLECULAR BIOLOGY, 2006, 357 (04) :1202-1210
[83]   Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats [J].
Davis, Myrtle ;
Bunin, Deborah I. ;
Samuelsson, Steven J. ;
Altera, Kenneth P. ;
Kinders, Robert J. ;
Lawrence, Scott M. ;
Ji, Jiuping ;
Ames, Matthew M. ;
Buhrow, Sarah A. ;
Walden, Chad ;
Reid, Joel M. ;
Rausch, Linda L. ;
Parman, Toufan .
TOXICOLOGIC PATHOLOGY, 2015, 43 (04) :519-529
[84]   Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours [J].
de Jonge, MJA ;
Kaye, S ;
Verweij, J ;
Brock, C ;
Reade, S ;
Scurr, M ;
van Doorn, L ;
Verheij, C ;
Loos, W ;
Brindley, C ;
Mistry, P ;
Cooper, M ;
Judson, I .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1459-1465
[85]   BN80927:: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo [J].
Demarquay, D ;
Huchet, M ;
Coulomb, H ;
Lesueur-Ginot, L ;
Lavergne, O ;
Camara, J ;
Kasprzyk, PG ;
Prévost, G ;
Bigg, DCH .
CANCER RESEARCH, 2004, 64 (14) :4942-4949
[86]   DNA cleavage assay for the identification of topoisomerase I inhibitors [J].
Dexheimer, Thomas S. ;
Pommier, Yves .
NATURE PROTOCOLS, 2008, 3 (11) :1736-1750
[87]   Furanocoumarins: Novel topoisomerase I inhibitors from Ruta graveolens L. [J].
Diwan, Renuka ;
Malpathak, Nutan .
BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (19) :7052-7055
[88]   New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives as Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations [J].
Dong, Guoqiang ;
Wang, Shengzheng ;
Miao, Zhenyuan ;
Yao, Jianzhong ;
Zhang, Yongqiang ;
Guo, Zizhao ;
Zhang, Wannian ;
Sheng, Chunquan .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (17) :7593-7613
[89]   Selection of Evodiamine as a Novel Topoisomerase I Inhibitor by Structure-Based Virtual Screening and Hit Optimization of Evodiamine Derivatives as Antitumor Agents [J].
Dong, Guoqiang ;
Sheng, Chunquan ;
Wang, Shengzheng ;
Miao, Zhenyuan ;
Yao, Jianzhong ;
Zhang, Wannian .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (21) :7521-7531
[90]  
Dong P, 2012, China patent no., Patent No. [2012051926, CN102764260. A, 102764260]